RxDoctor Payments Data

Thomas van Den Driessche, MD

Family Medicine · Fort Wayne, INNPI 1073507745

Payments from drug & device makers

$426in general payments, 2019–2025

Across 22 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$164
  • Medtronic$103
  • Otsuka America Pharmaceutical, Inc.$89
  • Pfizer$23
  • Sun Pharmaceutical Industries Inc.$20
  • Acadia Pharmaceuticals Inc$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$426 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$242,519
Medicare patients
755
Services billed
2,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,636$414,950
Invega SustennaPaliperidone Palmitate33$101,345
EnbrelEtanercept12$88,406
TrulicityDulaglutide107$87,648
Humira(Cf) PenAdalimumab12$87,420
TradjentaLinagliptin343$80,762
JardianceEmpagliflozin256$70,552
OzempicSemaglutide66$69,113
XifaxanRifaximin36$67,445
GemtesaVibegron394$64,676
XareltoRivaroxaban241$61,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$36,620
Abilify MaintenaAripiprazole12$34,279
Atorvastatin Calcium2,610$29,703
Breo ElliptaFluticasone/Vilanterol69$29,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$414,9501,636 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$89$53,22744 claims
AstraZenecaFarxiga$13$11,64633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →